For the quarter ended December 2025, AbbVie (ABBV) reported revenue of $16.62 billion, up 10% over the same period last year. EPS came in at $2.71, compared to $2.16 in the year-ago quarter.
The reported revenue represents a surprise of +1.58% over the Zacks Consensus Estimate of $16.36 billion. With the consensus EPS estimate being $2.66, the EPS surprise was +2.02%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how AbbVie performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Revenue- Humira- US: $897 million compared to the $574.85 million average estimate based on five analysts. The reported number represents a change of -28% year over year.
- Net Revenue- Humira- International: $349 million versus $374.4 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -20% change.
- Net Revenue- Oncology- Elahere- Total: $182 million compared to the $191.62 million average estimate based on five analysts. The reported number represents a change of +23% year over year.
- Net Revenue- Qulipta- International: $43 million versus $39.74 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +186.7% change.
- Net Revenue- Juvederm Collection- Total: $249 million compared to the $272.17 million average estimate based on five analysts. The reported number represents a change of -10.8% year over year.
- Net Revenue- Vraylar- Total: $1.02 billion compared to the $994.67 million average estimate based on five analysts. The reported number represents a change of +10.6% year over year.
- Net Revenue- Imbruvica: $671 million versus the five-analyst average estimate of $714.9 million. The reported number represents a year-over-year change of -20.9%.
- Net Revenue- Eye Care- Total: $580 million versus the five-analyst average estimate of $568.88 million. The reported number represents a year-over-year change of -10.2%.
- Net Revenue- Botox Therapeutic- Total: $990 million versus the five-analyst average estimate of $995.91 million. The reported number represents a year-over-year change of +13.4%.
- Net Revenue- Aesthetics- Total: $1.29 billion compared to the $1.28 billion average estimate based on five analysts. The reported number represents a change of -0.9% year over year.
- Net Revenue- Venclexta: $710 million compared to the $725.34 million average estimate based on five analysts. The reported number represents a change of +8.4% year over year.
- Net Revenues- Neuroscience- Vyalev: $183 million versus $170.15 million estimated by five analysts on average.
View all Key Company Metrics for AbbVie here>>>
Shares of AbbVie have returned +0.8% over the past month versus the Zacks S&P 500 composite's +0.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
